Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorder

American Journal of Psychiatry

Volumn 154, Issue 5, 1997, Pages 700-702

  Brawman Mintzer, Olga ^a   Lydiard, R Bruce ^b   Bradwejn, Jacques ^b   Villarreal, Gerardo ^b   Knapp, Rebecca ^b   Emmanuel, Naresh ^b   Ware, Michael R ^b   He, Qin ^b   Ballenger, James C ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PENTAGASTRIN;

ADULT; ARTICLE; BOLUS INJECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; MALE; PANIC; PRIORITY JOURNAL;

EID: 0030951183     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.154.5.700     Document Type: Article

References (4)

1. Harro J, Vasar E, Bradwejn J: CCK in animal and human research on anxiety. Trends Pharmacol Sci 1993; 14:244-249
2. Bradwejn J, Koszycki D, Annable L, Couetoux du Tertre A, Reines S, Karkanias C: A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder. Biol Psychiatry 1992; 32:903-912
3. Abelson JL, Nesse RM: Pentagastrin infusions in patients with panic disorder, I: symptoms and cardiovascular responses. Biol Psychiatry 1994; 36:73-83
4. Bradwejn J, Koszycki D, Bourin M: Dose ranging study of the effect of CCK-4 in healthy volunteers. J Psychiatry Neurosci 1991; 16:260-264